HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic pontine glioma.

Stacie S Wang Alexander J DavenportMelinda IliopoulosHannah E Hughes-Parry Katherine A Watson Valeria Arcucci Matthias Mulazzani David D Eisenstat Jordan R Hansford Ryan S Cross Misty R Jenkins

Published in: Neuro-oncology advances (2023)

HER2 CAR T cells are already in clinic development and are well tolerated in pediatric patients. Here we provide strong preclinical evidence for the inclusion of DIPG patients in future pediatric CNS tumor HER2 CAR T cell clinical trials.

Keyphrases

clinical trial
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
mesenchymal stem cells
current status
randomized controlled trial
patient reported outcomes
combination therapy
open label